Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Comprehensive Overview
Published in the New England Journal of Medicine in 2015, this study, known as the EMPA-REG OUTCOME trial, asked whether empagliflozin, a drug that lowers blood sugar by blocking glucose reabsorption in the kidney, could reduce cardiovascular events and death in people with type 2 diabetes at high cardiovascular risk, a question that mattered because earlier glucose-lowering drugs had never convincingly shown that better blood sugar control translates into fewer heart attacks or strokes. Researchers conducted a randomized, double-blind, placebo-controlled trial in which patients with type 2 diabetes and established cardiovascular disease, treated at 590 sites in 42 countries, received 10 milligrams or 25 milligrams of empagliflozin, or placebo, once daily on top of their standard care, and followed 7,020 treated patients for a median observation time of 3.1 years. The primary outcome was a composite of death from cardiovascular causes, nonfatal heart attack, or nonfatal stroke, comparing the pooled empagliflozin groups against placebo, with a key secondary outcome that also counted hospitalization for unstable angina. The topline result was that empagliflozin significantly reduced the primary composite outcome and also reduced death from any cause, even though the trial found no significant effect on heart attack or stroke individually.
Outcomes and Implications
The most important finding was that the primary composite outcome occurred in 10.5% of patients receiving empagliflozin compared with 12.1% of those receiving placebo, and that this benefit was driven almost entirely by a striking 38% relative reduction in death from cardiovascular causes, since rates of heart attack and stroke themselves did not differ significantly between groups. Empagliflozin also reduced hospitalization for heart failure by 35% and, notably, lowered death from any cause by 32%, a rare and clinically important finding for a diabetes drug given how few glucose-lowering therapies have ever demonstrated a mortality benefit. These reductions in cardiovascular and all-cause death emerged early and were sustained throughout the trial, and the relative reduction in death from any cause meant that only 39 patients needed treatment for 3 years to prevent one death. The key secondary outcome, which added hospitalization for unstable angina, did not reach statistical significance, and there was no clear difference between the two empagliflozin doses. The main safety signal was a higher rate of genital infection with empagliflozin, though diabetic ketoacidosis, volume depletion, and kidney-related adverse events were low and similar between groups, with acute renal failure actually less common with empagliflozin than placebo. The authors conclude that among patients with type 2 diabetes at high cardiovascular risk, adding empagliflozin to standard care lowered the rate of major cardiovascular events and death from any cause, though the mechanisms behind this benefit remain speculative and likely multifactorial.